Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–451 of 451 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Ritonavir (rtv) Clear all

Conditions: HIV Infections
Interventions: Raltegravir and truvada, Atazanavir, Norvir and Truvada; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HER2-positive Advanced Solid Tumor
Interventions: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole; Biological · Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Cerritos, California • Los Angeles, California • San Diego, California + 29 more

Conditions: HIV, HIV Infections, Pregnancy
Interventions: Darunavir, Ritonavir, Etravirine, Rilpivirine, Darunavir/Cobicistat (FDC); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 16
States / cities: Daytona Beach, Florida • Jacksonville, Florida • Miami, Florida + 13 more

Conditions: Healthy Volunteer
Interventions: danoprevir, methadone, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Anaheim, California • Overland Park, Kansas

Conditions: Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
Interventions: Raltegravir, Atazanavir, Standard treatment regimen; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: New Haven, Connecticut • Waterbury, Connecticut • West Haven, Connecticut + 1 more

Conditions: HIV Infection
Interventions: Aprepitant; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Human Immunodeficiency Virus - Type 1
Interventions: Darunavir (DRV), Ritonavir (rtv); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more

Conditions: HIV-1 Infection
Interventions: B/F/TAF, NRTIs, Third Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more

Conditions: HIV Infections, Lipodystrophy, Wasting Disease
Interventions: Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 25
States / cities: Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more

Conditions: HIV Infections
Interventions: Truvada, Atazanavir, Ritonavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Foster City, California

Conditions: HIV Infections
Interventions: tipranavir, ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Providence, Rhode Island + 2 more

Conditions: Healthy
Interventions: JNJ-61393215, Ritonavir; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions: Docetaxel in Parenteral Dosage Form, ModraDoc006/r; Drug
Lead sponsor: Modra Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Detroit, Michigan • Las Vegas, Nevada • Portland, Oregon + 1 more

Conditions: Hepatitis D
Interventions: Lonafarnib, Ritonavir, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Atazanavir/Ritonavir/Lopinavir/ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Hepatic Impairment
Interventions: PF-07321332, Ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Tustin, California • Saint Paul, Minnesota

Conditions: HIV-1 Infection
Interventions: Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more

Conditions: COVID-19, SARS-CoV-2
Interventions: Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 6
States / cities: Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more

Search by objective public record fields.

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

A Study on the Interaction Between Danoprevir/Ritonavir and Methadone

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Treatment for COVID-19 in High-Risk Adult Outpatients